

## The Role of Postoperative Radiotherapy on Stage N2 Non-small Cell Lung Cancer

Fangfang DU, Zhiyong YUAN, Jun WANG, Lujun ZHAO, Qingsong PANG, Liqun GONG, Changli WANG, Ping WANG

### 摘要

**Background and objective** The clinical value of postoperative radiotherapy (PORT) in stage N2 nonsmall-cell lung cancer (NSCLC) is controversy. The aim of this study is to analyze the efficacy of PORT in subgroup of stage N2 NSCLC, which can help clinicians to choose proper patients for PORT. **Methods** Clinical data of 359 patients with stage N2 NSCLC treated with radical surgery between Mar. 2000 and Jul. 2005 were retrospectively reviewed. Two hundred and seven patients received adjuvant chemotherapy and one hundred and four patients received adjuvant radiotherapy. First, the group of patients were analyzed to evaluate the factors affecting the overall survival. The all patients were divided based on tumor size and the number of lymph node metastasis station (single station or multiple station) so as to evaluate the role of PORT. The endpoint was overall survival (OS) and local recurrence-free survival (LRFS). Kaplan-Meier method was used to calculate the OS, LRFS and Log-rank was used to compare the difference in OS and LRFS between different groups. **Results** The median duration of follow-up was 2.3 years. 224 patients died. The median survival was 1.5 years and 1, 3, 5-year survival were 78%, 38% and 26%. Univariate analysis showed tumor size, the number of lymph node metastasis station and PORT were correlated with OS. Among patients, 5-year survival rates in PORT and non-PORT were 29% and 24% ( $P=0.047$ ) respectively. In subgroups, PORT was related with high survival in patients with multiple station N2 compared to non-PORT: 36% vs 20% ( $P=0.013$ ) and 33% vs 15% ( $P=0.002$ ) in patients in patients with tumor size > 3 cm. Also, it was related with low local recurrence compared to non-PORT: 65% vs 48% ( $P=0.006$ ) and 62% vs 48% ( $P=0.033$ ). **Conclusion** PORT can improve overall survival for N2 NSCLC, especially the patients with the factors as follows: tumor size > 3 cm and multiple station N2 can benefit from PORT more or less.






全文: [PDF](#) [HTML](#)







主编  
Qinghua Zhou  
Yan Sun



### ARTICLE TOOLS

-  [索引源数据](#)
-  [如何引证项目](#)
-  [查找参考文献](#)
-  [审查政策](#)
-  [Email this article \(Login required\)](#)

### RELATED ITEMS

-  [Related studies](#)
-  [Databases](#)
-  [Web search](#)
-  [Show all](#)

### ABOUT THE AUTHORS

- [Fangfang DU](#)
- [Zhiyong YUAN](#)
- [Jun WANG](#)
- [Lujun ZHAO](#)
- [Qingsong PANG](#)
- [Liqun GONG](#)
- [Changli WANG](#)
- [Ping WANG](#)



肿瘤防治研究  
CANCER RESEARCH ON PREVENTION AND TREATMENT



Pioneer Bioscience  
Publishing Company  
PBPC [www.thePBPC.org](http://www.thePBPC.org)

J Thorac Dis

